From GlobeNewswire: 2025-06-05 09:40:00

The Multiplex Assay Market was valued at USD 3.05 billion in 2023 and is projected to reach USD 8.84 billion by 2032, growing at a CAGR of 11.24%. North America led in 2023, with the U.S. holding over 60% market share due to rising demand for personalized medicine and FDA approvals for companion diagnostics. Multiplex assays offer rapid, high-throughput detection of multiple targets, benefiting applications in infectious disease, oncology, and immunology.

Multiplex assays have transformed clinical and research diagnostics by allowing simultaneous detection of multiple analytes. Adoption is accelerating in disease surveillance, vaccine development, autoimmune disease diagnostics, and oncology. Regulatory backing and a shift towards decentralized diagnostics are making multiplex technologies standard tools in precision healthcare, particularly in developed nations.

Consumables were the largest product category in 2023, with a 45% market share, driven by their inclusion in assay protocols, routine diagnostic use, and an expanding portfolio of testing kits. Software is the fastest-growing product category. Flow cytometry held 40% market share in 2023, valued for its use in immunophenotyping and cell-based assays in oncology and immunology studies. Pharmaceutical and biotechnology companies led the end-user segment in 2023, leveraging multiplex assays extensively in biomarker validation and drug target identification.

North America, particularly the U.S., held about 60% of the global market in 2023, with significant growth driven by major assay developers, established healthcare facilities, and high investments in personalized diagnostics. The Asia Pacific is expected to register the fastest growth during the forecast period, driven by enhancements in healthcare infrastructure, increasing biotech research investment, and growing prevalence of chronic and infectious diseases.

Recent developments in the Multiplex Assay Market include Thermo Fisher’s TaqMan Multiplex Assay for quantitative PCR, Bio-Rad Laboratories’ Bio-Plex Pro Human Cytokine 17-plex Panel, and Abcam’s high-throughput solution for FirePlex. SNS Insider is a global market research and consulting agency providing clients with accurate market data, consumer insights, and opinions to make confident decisions in changing circumstances.



Read more at GlobeNewswire: Multiplex Assay Market Set to Reach USD 8.84 Billion by